Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.
Snell D, Gunde T, Warmuth S, Chatterjee B, Brock M, Hess C, Johansson M, Simonin A, Spiga FM, Weinert C, Kirk N, Bassler N, Campos Carrascosa L, Flückiger N, Heiz R, Wagen S, Giezendanner N, Alberti A, Yaman Y, Mahler D, Diem D, Lichtlen P, Urech D. Snell D, et al. Oncoimmunology. 2023 Jul 12;12(1):2233401. doi: 10.1080/2162402X.2023.2233401. eCollection 2023. Oncoimmunology. 2023. PMID: 37456982 Free PMC article.
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.
Warmuth S, Gunde T, Snell D, Brock M, Weinert C, Simonin A, Hess C, Tietz J, Johansson M, Spiga FM, Heiz R, Flückiger N, Wagen S, Zeberer J, Diem D, Mahler D, Wickihalder B, Muntwiler S, Chatterjee B, Küttner B, Bommer B, Yaman Y, Lichtlen P, Urech D. Warmuth S, et al. Among authors: snell d. Oncoimmunology. 2021 Dec 2;10(1):2004661. doi: 10.1080/2162402X.2021.2004661. eCollection 2021. Oncoimmunology. 2021. PMID: 35844969 Free PMC article.
A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis.
Tietz J, Gunde T, Warmuth S, Weinert C, Brock M, Simonin A, Hess C, Johansson M, Spiga F, Muntwiler S, Wickihalder B, Mahler D, Diem D, Zeberer J, Heiz R, Flückiger N, Shiraishi N, Miyake Y, Takahashi N, Fehrholz M, Bertolini M, Lichtlen P, Urech D, Snell D. Tietz J, et al. Among authors: snell d. JID Innov. 2024 Jan 16;4(2):100258. doi: 10.1016/j.xjidi.2024.100258. eCollection 2024 Mar. JID Innov. 2024. PMID: 38375189 Free PMC article.
Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins.
Foord E, Klynning C, Schoutrop E, Förster JM, Krieg J, Mörtberg A, Müller MR, Herzog C, Schiegg D, Villemagne D, Fiedler U, Snell D, Kebble B, Mattsson J, Levitsky V, Uhlin M. Foord E, et al. Among authors: snell d. J Immunol Res. 2020 Aug 4;2020:7375947. doi: 10.1155/2020/7375947. eCollection 2020. J Immunol Res. 2020. PMID: 32832572 Free PMC article.
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma.
Biswas D, Liu YH, Herrero J, Wu Y, Moore DA, Karasaki T, Grigoriadis K, Lu WT, Veeriah S, Naceur-Lombardelli C, Magno N, Ward S, Frankell AM, Hill MS, Colliver E, de Carné Trécesson S, East P, Malhi A, Snell DM, O'Neill O, Leonce D, Mattsson J, Lindberg A, Micke P, Moldvay J, Megyesfalvi Z, Dome B, Fillinger J, Nicod J, Downward J, Szallasi Z; TRACERx Consortium; Hackshaw A, Jamal-Hanjani M, Kanu N, Birkbak NJ, Swanton C. Biswas D, et al. Among authors: snell dm. Nat Cancer. 2025 Jan 9. doi: 10.1038/s43018-024-00883-1. Online ahead of print. Nat Cancer. 2025. PMID: 39789179
151 results